ArticleJournal of cancer research and clinical oncology2015
Epigenetically silenced long noncoding-SRHC promotes proliferation of hepatocellular carcinoma.
Article in Journal of cancer research and clinical oncology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 1 synthesis or guideline pooled it, 37 citations in OpenAlex.
- Diagnostic value of long noncoding RNAs for hepatocellular carcinoma: A PRISMA-compliant meta-analysis.Medicine · 2017Pooled it
- The epigenetic regulatory network of long noncoding RNAs in hepatocellular carcinoma.Genes & diseases · 2025Review
- Deciphering the methylation landscape of long noncoding RNAs in hepatocellular carcinoma: a focus on LINC00942.Clinical epigenetics · 2025Article
- DNMT1-mediated demethylation of lncRNA MEG3 promoter suppressed breast cancer progression by repressing Notch1 signaling pathway.Cell cycle (Georgetown, Tex.) · 2022Article
- The Mechanism Underlying the ncRNA Dysregulation Pattern in Hepatocellular Carcinoma and Its Tumor Microenvironment.Frontiers in immunology · 2022Review
- Advances in Multi-Omics Applications in HBV-Associated Hepatocellular Carcinoma.Frontiers in medicine · 2021Review
- Article
- A prognostic model composed of four long noncoding RNAs predicts the overall survival of Asian patients with hepatocellular carcinoma.Cancer medicine · 2020Article
- New LncRNAs in Chronic Hepatitis C progression: from fibrosis to hepatocellular carcinoma.Scientific reports · 2020Article
- Screening and verification of long noncoding RNA promoter methylation sites in hepatocellular carcinoma.Cancer cell international · 2020Article
- Article
- Long Non-coding RNA Zinc Finger Antisense 1 (ZFAS1) Regulates Proliferation, Migration, Invasion, and Apoptosis by Targeting MiR-7-5p in Colorectal Cancer.Medical science monitor : international medical journal of experimental and clinical research · 2019Article
- Article
- A Survey of Molecular Heterogeneity in Hepatocellular Carcinoma.Hepatology communications · 2018Article
- DNA methylation contributes to silencing the expression of linc00086 in gastric cancer.Oncology letters · 2018Article
- Therapeutic targeting of noncoding RNAs in hepatocellular carcinoma: Recent progress and future prospects.Oncology letters · 2018Article
- Behind the curtain of non-coding RNAs; long non-coding RNAs regulating hepatocarcinogenesis.World journal of gastroenterology · 2018Review
- Hypermethylation of MEG3 promoter correlates with inactivation of MEG3 and poor prognosis in patients with retinoblastoma.Journal of translational medicine · 2017Article
- Exosomes-mediated transfer of long noncoding RNA ZFAS1 promotes gastric cancer progression.Journal of cancer research and clinical oncology · 2017Article
- Long Noncoding RNAs as a Key Player in Hepatocellular Carcinoma.Biomarkers in cancer · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo investigate the expression of SRHC and the role of SRHC in the pathogenesis of hepatocellular carcinoma (HCC).
methodsWe analyzed HCC samples and matched non-tumor liver tissues (controls) collected from 81 patients who underwent hepatectomy in Shanghai, China. The expression levels of SRHC were determined by quantitative reverse-transcription polymerase chain reaction. Statistical analyses were used to associate the levels of SRHC with tumor features and patient outcomes.
resultsWe found that a lower SRHC expression level was significantly more frequent in tissues with a high serum a-fetoprotein level (positive, >20 µg/L, P = 0.004) and a low degree of differentiated tumors (poorly differentiated, P = 0.017). Furthermore, we found that the promoter region of SRHC contains a CpG-rich island and that SRHC is down-regulated in tumors by DNA methylation.
conclusionHere, we identified a new long noncoding RNA designated as SRHC that is capable of inhibiting cancer proliferation and is down-regulated in tumors at least partly by DNA methylation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.